Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
- Novo 近 90 天出现 6 次
- 上一次：7 天前 · After capital-markets day flop, Novo strikes licensing deal that sends a Swedish company’s stock soaring
发生了什么
Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.
摘要按规则整理自下方来源原文